This multi-volume, state-of-the-art encyclopedia discusses all preclinical, clinical, toxicological, regulatory and marketing perspectives of drug metabolism and interactions. Methods and detailed protocols describing how to perform studies of metabolism and drug interactions are presented in one of the volumes. All aspects of drug metabolism and interactions in silico, in laboratory animals and in humans, are backed with a range of examples. This reference is essential for researchers interested in all aspects of drug development, and chemists, pharmacologists, pharmaceutical specialists,…mehr
This multi-volume, state-of-the-art encyclopedia discusses all preclinical, clinical, toxicological, regulatory and marketing perspectives of drug metabolism and interactions. Methods and detailed protocols describing how to perform studies of metabolism and drug interactions are presented in one of the volumes. All aspects of drug metabolism and interactions in silico, in laboratory animals and in humans, are backed with a range of examples. This reference is essential for researchers interested in all aspects of drug development, and chemists, pharmacologists, pharmaceutical specialists, toxicologists, molecular toxicologists, and clinicians including practitioners and physicians.
ALEXANDER V. LYUBIMOV, MD, PhD, DABT, is Director of the Toxicology Research Laboratory and Associate Professor of Pharmacology at the University of Illinois at Chicago. He has more than thirty years of experience in the fields of toxicology, bioanalytical chemistry, and drug efficacy. He has presented his research results at more than fifty national and international scientific conferences. In addition, he has published more than 140 scientific publications in peer-reviewed journals, books, and conference proceedings. Dr. Lyubimov has served as chair or president of several international conferences, including "Frontiers of Pharmacology and Toxicology," which he also organized.
Inhaltsangabe
Contributors ix
Preface to the Encyclopedia xxiii
Preface--Volume 6 xxvii
PART X Clinical Aspects of Drug Metabolism and Interactions 1
1 Clinical Aspects of Drug Biotransformation: An Overview 3 Michael D. Coleman and Louis L. Radulovic
2 CYP450 Enzymes in Drug Discovery and Development: An Overview 53 Lin Xu, Biplab Das, and Chandra Prakash
3 DDI Risk Assessment and Evaluation in Pharmaceutical Development: Interfacing Drug Metabolism and Clinical Pharmacology 89 Karthik Venkatakrishnan
4 Current and Future Tools for Predicting Clinical Drug-Drug Interactions 151 Peter L. Bullock and Olga V. Trubetskoy
5 Predicting Human Biotransformation Pathways 177 Shelby Anderson, Debra Luffer-Atlas, and Mary Pat Knadler
6 Conjugation, Transport, and Elimination of Drugs in Humans 205 Ronald E. Savage
7 Role and Clinical Consequences of Human UDP-Glucuronosyltransferases 243 Deepak K. Dalvie and Cho-Ming Loi
8 Herb-Drug and Food-Drug Interactions 279 Martin S. Lennard
9 Effects of Liver Disease on Drug Metabolism in Humans 307 Hui-Hui Tan and Thomas D. Schiano
10 Role of Phase I Metabolism in Drug Activation and Clinical Treatment Outcomes 353 Bernard Testa and André Pannatier
11 Role of Metabolism in Toxicity of Drugs in Humans 377 Amit S. Kalgutkar and Jonathan N. Bauman
12 Idiosyncratic Drug Reactions and the Potential Role of Metabolism 403 Jack P. Uetrecht
PART XI Metabolism of Specific Drug Groups and Patient Populations 455 13 Metabolism of Psychotropic Drugs 457
Julia Stingl, Jessica Oesterheld, and Miia Turpeinen
14 Metabolism-Based Consequences of Polytherapy with Antiepileptic Drugs 473 Philip N. Patsalos
15 Oral Chemotherapeutic Agents 499 Shin Ogita, Patricia LoRusso, and Jing Li
16 Drug Metabolism and Interactions in Pediatric Patients 537 Souzan Yanni and Karel Allegaert
17 Population-Based Pharmacokinetic Modeling and Simulation 581 Frédéric Y. Bois and Masoud Jamei
18 Clinical Pharmacology in Drug Labeling. The Impact of Drug Metabolism and Clinical Pharmacology on Recommended Dose of Drugs 609 Stuart Dombey
